Thursday, August 15, 2019 - Insilico Medicine, a biotechnology company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at Targeting Metabesity 2019 in Washington, on October 16.
"Metabesity" refers to the constellation of chronic diseases of aging, including diabetes, obesity, cardiovascular and neurodegenerative diseases, cancer, and the aging process itself, that have common metabolic roots and thus may be susceptible to common solutions, notably disease delay and prevention. Targeting Metabesity 2019 will be a silo-busting interrogation of what scientific, policy, economic, and social structures can catalyze disease prevention and the extension of healthy lifespan.
"Targeting Metabesity 2019 focuses on some of the most important issues in healthcare today: increasing the focus on chronic, not just acute, diseases; shifting the emphasis from treatment to prevention; and going beyond managing individual diseases to extending healthy lifespan," said Drs. Alexander Fleming and Lawrence Steinman, conference organizers.
"I am happy to present our latest research at Targeting Metabesity 2019, which gathers the leading longevity leaders. The topic of artificial intelligence for drug discovery is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," said Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine.
Artificial intelligence has the potential to transform the pharmaceutical industry, making the hunt for new pharmaceuticals quicker and more effective. With AI comes the potential to improve drug approval rates, reduce development costs, and help patients comply with their treatments. At Insilico, artificial intelligence has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, artificial intelligence helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.
For further information, images or interviews, please contact:
Contact: Klug Gehilfe email@example.com
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
About Insilico Medicine
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief.
Brief company video: https:/